BRCA2 and liposarcoma: Partial responses were achieved in two cases: a liposarcoma patient with a BRCA2 mutation treated with PARP inhibitors (Olaparib and Talazoparib; PFS 29.5 months) and a patient with an NTRK1 fusion who received Larotrectinib (PFS 57.7 months).